Hammersmith Hospital, Imperial College Healthcare NHS Trust

London W120HS

3 studies enrolling now · 6 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml, Intrahepatic Cholangiocarcinoma, Neoplasms, Ovarian Cancer, Sickle Cell Disease

Studies at this site

• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — Recruiting now
• A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia — Recruiting now
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma — Stopped early
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed